Déborah Bauer

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania et al. · New England Journal of Medicine · 2023 · 407 citations · Full text

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

Patrick Vermersch, Anna Członkowska, Luigi ME Grimaldi et al. · Multiple Sclerosis Journal · 2013 · 348 citations · Full text

Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder

Herbert Y. Meltzer, Lisa A. Arvanitis, Déborah Bauer et al. · American Journal of Psychiatry · 2004 · 331 citations

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

Gerd R Burmester, Yong Lin, Rahul Patel et al. · Annals of the Rheumatic Diseases · 2016 · 306 citations · Full text

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Aaron Miller, Jerry S. Wolinsky, Ludwig Kappos et al. · The Lancet Neurology · 2014 · 295 citations

Oral Teriflunomide, Neurological Disorder, Symptomatic Treatment +5